887 results on '"Naito, Tateaki"'
Search Results
52. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non–small-cell Lung Cancer
53. Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer
54. Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein
55. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments
56. Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non–Small-cell Lung Cancer by Amplicon-based Massively Parallel Sequencing
57. Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
58. Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy
59. Correction to: Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
60. Acquired immunodeficiency associated with thymoma: a case report
61. A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol
62. Impact of Early Chemotherapy Resumption on the Outcome after Staphylococcus aureus Bacteremia in Patients with Solid Tumors: A Retrospective Study in a Single Tertiary Cancer Center in Japan.
63. Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status
64. Disease flare after gef itinib discontinuation
65. Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study
66. Crizotinib-induced simultaneous multiple cardiac toxicities
67. Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy
68. Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer
69. Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer
70. Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer
71. Negative impact of leukoaraiosis on the incidence of brain metastases in patients with lung cancer
72. Skeletal muscle loss and prognosis of breast cancer patients
73. The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum
74. Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?
75. Toxicity and efficacy of chemotherapy for non-small cell lung cancer with cavitary lesions
76. Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy
77. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients
78. Characteristics of cellular composition in malignant pericardial effusion and its association with the clinical course of carcinomatous pericarditis
79. Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)
80. The effects of advanced age and serum α1‐acid glycoprotein on docetaxel unbound exposure and dose‐limiting toxicity in cancer patients
81. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study
82. Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy
83. Clinical impact of tumour burden on the efficacy of PD ‐1/ PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer
84. O15-1 Responder analysis of anamorelin in patients with cancer cachexia
85. MO44-5 The clinical outcome of patients with oligometastatic non-small cell lung cancer treated with first-line immunotherapy
86. EL08 Supportive care in cancer
87. Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer
88. Dose-Escalation Study of Three-Dimensional Conformal Thoracic Radiotherapy With Concurrent S-1 and Cisplatin for Inoperable Stage III Non–Small-Cell Lung Cancer
89. Cardiac Dysfunction Caused by Osimertinib
90. Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non‐small cell lung cancer
91. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy
92. Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: A retrospective study in Japan
93. Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study.
94. The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor
95. Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer
96. The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients
97. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease
98. 18F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: A clinicopathological study
99. Phase I Results of Vinorelbine With Concurrent Radiotherapy in Elderly Patients With Unresectable, Locally Advanced Non-Small-Cell Lung Cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI)
100. Impact of chemotherapy resumption on the outcome of Staphylococcus aureus bacteremia in patients with solid tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.